{"id":44602,"date":"2025-10-27T22:10:15","date_gmt":"2025-10-27T14:10:15","guid":{"rendered":"https:\/\/flcube.com\/?p=44602"},"modified":"2025-10-27T22:10:16","modified_gmt":"2025-10-27T14:10:16","slug":"chugai-to-acquire-renalys-pharma-for-jpy-31-billion-to-expand-iga-nephropathy-treatment-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44602","title":{"rendered":"Chugai to Acquire Renalys Pharma for JPY 31 Billion to Expand IgA Nephropathy Treatment Portfolio"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Chugai Pharmaceutical, a member of the Roche Group, announced on October 24, 2025, that it will acquire all shares of Tokyo-based Renalys Pharma, making it a wholly-owned subsidiary. This strategic move secures exclusive rights for sparsentan in Japan, South Korea, and Taiwan.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Renalys Pharma Background<\/strong><br>Renalys Pharma, established in April 2023 with funding from Catalys Pacific and SR One, holds exclusive development and commercialization rights for sparsentan in Japan, South Korea, and Taiwan. Sparsentan, an oral small-molecule drug for IgA nephropathy (IgAN), was launched in the US as FILSPARI in February 2023 and approved in Europe in April 2024. It is currently undergoing a Phase III clinical trial in Japan.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Transaction Details<\/strong><br>The total transaction consideration could reach up to JPY 31 billion (over USD 200 million). Chugai will pay an upfront cash payment of JPY 15 billion (approximately USD 98 million) upon closing. Additional payments of up to JPY 16 billion in milestones and sales royalties are contingent on sparsentan&#8217;s regulatory approval and sales performance in the three markets.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Strategic Fit<\/strong><br>Sparsentan is expected to complement Chugai&#8217;s own IgA nephropathy nucleic acid drug, sefaxersen (development code: RG6299), which is currently in development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chugai Pharmaceutical, a member of the Roche Group, announced on October 24, 2025, that it&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44605,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[382,163],"class_list":["post-44602","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-chugai-pharmaceutical","tag-roche"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Chugai to Acquire Renalys Pharma for JPY 31 Billion to Expand IgA Nephropathy Treatment Portfolio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Chugai Pharmaceutical, a member of the Roche Group, announced on October 24, 2025, that it will acquire all shares of Tokyo-based Renalys Pharma, making it a wholly-owned subsidiary. This strategic move secures exclusive rights for sparsentan in Japan, South Korea, and Taiwan.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44602\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chugai to Acquire Renalys Pharma for JPY 31 Billion to Expand IgA Nephropathy Treatment Portfolio\" \/>\n<meta property=\"og:description\" content=\"Chugai Pharmaceutical, a member of the Roche Group, announced on October 24, 2025, that it will acquire all shares of Tokyo-based Renalys Pharma, making it a wholly-owned subsidiary. This strategic move secures exclusive rights for sparsentan in Japan, South Korea, and Taiwan.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44602\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-27T14:10:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-27T14:10:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2708.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44602#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44602\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Chugai to Acquire Renalys Pharma for JPY 31 Billion to Expand IgA Nephropathy Treatment Portfolio\",\"datePublished\":\"2025-10-27T14:10:15+00:00\",\"dateModified\":\"2025-10-27T14:10:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44602\"},\"wordCount\":203,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44602#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2708.webp\",\"keywords\":[\"Chugai Pharmaceutical\",\"Roche\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44602#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44602\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44602\",\"name\":\"Chugai to Acquire Renalys Pharma for JPY 31 Billion to Expand IgA Nephropathy Treatment Portfolio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44602#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44602#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2708.webp\",\"datePublished\":\"2025-10-27T14:10:15+00:00\",\"dateModified\":\"2025-10-27T14:10:16+00:00\",\"description\":\"Chugai Pharmaceutical, a member of the Roche Group, announced on October 24, 2025, that it will acquire all shares of Tokyo-based Renalys Pharma, making it a wholly-owned subsidiary. This strategic move secures exclusive rights for sparsentan in Japan, South Korea, and Taiwan.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44602#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44602\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44602#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2708.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2708.webp\",\"width\":1080,\"height\":608,\"caption\":\"Chugai to Acquire Renalys Pharma for JPY 31 Billion to Expand IgA Nephropathy Treatment Portfolio\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44602#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chugai to Acquire Renalys Pharma for JPY 31 Billion to Expand IgA Nephropathy Treatment Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chugai to Acquire Renalys Pharma for JPY 31 Billion to Expand IgA Nephropathy Treatment Portfolio - Insight, China&#039;s Pharmaceutical Industry","description":"Chugai Pharmaceutical, a member of the Roche Group, announced on October 24, 2025, that it will acquire all shares of Tokyo-based Renalys Pharma, making it a wholly-owned subsidiary. This strategic move secures exclusive rights for sparsentan in Japan, South Korea, and Taiwan.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44602","og_locale":"en_US","og_type":"article","og_title":"Chugai to Acquire Renalys Pharma for JPY 31 Billion to Expand IgA Nephropathy Treatment Portfolio","og_description":"Chugai Pharmaceutical, a member of the Roche Group, announced on October 24, 2025, that it will acquire all shares of Tokyo-based Renalys Pharma, making it a wholly-owned subsidiary. This strategic move secures exclusive rights for sparsentan in Japan, South Korea, and Taiwan.","og_url":"https:\/\/flcube.com\/?p=44602","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-27T14:10:15+00:00","article_modified_time":"2025-10-27T14:10:16+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2708.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44602#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44602"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Chugai to Acquire Renalys Pharma for JPY 31 Billion to Expand IgA Nephropathy Treatment Portfolio","datePublished":"2025-10-27T14:10:15+00:00","dateModified":"2025-10-27T14:10:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44602"},"wordCount":203,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44602#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2708.webp","keywords":["Chugai Pharmaceutical","Roche"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44602#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44602","url":"https:\/\/flcube.com\/?p=44602","name":"Chugai to Acquire Renalys Pharma for JPY 31 Billion to Expand IgA Nephropathy Treatment Portfolio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44602#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44602#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2708.webp","datePublished":"2025-10-27T14:10:15+00:00","dateModified":"2025-10-27T14:10:16+00:00","description":"Chugai Pharmaceutical, a member of the Roche Group, announced on October 24, 2025, that it will acquire all shares of Tokyo-based Renalys Pharma, making it a wholly-owned subsidiary. This strategic move secures exclusive rights for sparsentan in Japan, South Korea, and Taiwan.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44602#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44602"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44602#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2708.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2708.webp","width":1080,"height":608,"caption":"Chugai to Acquire Renalys Pharma for JPY 31 Billion to Expand IgA Nephropathy Treatment Portfolio"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44602#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Chugai to Acquire Renalys Pharma for JPY 31 Billion to Expand IgA Nephropathy Treatment Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2708.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44602"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44602\/revisions"}],"predecessor-version":[{"id":44606,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44602\/revisions\/44606"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44605"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}